Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135032 | 0.98 | TDP1 (1.00) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6114977 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6114843 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6115248 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25381701 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25381172 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25380936 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25382598 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| Bromide SCHEMBL15822430 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL6115279 | 0.96 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | claimed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | claimed |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-14 | — | — | US | claimed |
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | claimed |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-22 | — | — | US | claimed |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-08 | — | — | US | claimed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| WO-2013037896-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | TDP1 3133/4885L3MBTL1 2846/4885HRH1 3177/4885 |
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | CDK9, BRD4, CDK19 | TDP1 1555/4885L3MBTL1 1715/4885HRH1 3398/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | TDP1 3371/4885L3MBTL1 2724/4885HRH1 3427/4885 |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | TDP1 554/4885L3MBTL1 2205/4885HRH1 1821/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | TDP1 554/4885L3MBTL1 2205/4885HRH1 1821/4885 |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | TDP1 810/4885L3MBTL1 2465/4885HRH1 4607/4885 |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | TDP1 810/4885L3MBTL1 2465/4885HRH1 4607/4885 |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | TDP1 810/4885L3MBTL1 2465/4885HRH1 4607/4885 |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | TDP1 810/4885L3MBTL1 2465/4885HRH1 4607/4885 |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | TDP1 810/4885L3MBTL1 2465/4885HRH1 4607/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | TDP1 3133/4885L3MBTL1 2846/4885HRH1 3177/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | TDP1 3133/4885L3MBTL1 2846/4885HRH1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.